EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province

Maofang WU; Yongchun ZHOU; Jingjing CAI; Xin MO; Yinwei LI; Jiahui MAO

doi:10.12259/j.issn.2095-610X.S20220215

Volume 43 Issue 2

Mar. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(2): 60-66

Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province[J]. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215

Citation:

Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province[J]. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215

Citation:

Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province[J]. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215

PDF( 698 KB)

EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province

doi: 10.12259/j.issn.2095-610X.S20220215

1.
Dept. of Interventional Oncology，Qingbaijiang District People’s Hospital，Chengdu Sichuan ，610300
2.
Dept. of Yunnan Key Laboratory of Lung Cancer Research，Joint Laboratory of International Cooperation for Regional High-Incidence Tumors at High Altitude，Third Affiliated Hospital of Kunming Medical University，Yunnan Cancer Hospital， Yunnan Kunming 650118，China

Received Date: 2021-12-13
Available Online: 2022-02-24
Publish Date: 2022-03-04

Abstract

Abstract

Objective To investigate the relationship between EGFR gene mutations and clinicopathological characteristics of patients with multinodular lung adenocarcinoma in Yunnan province by using NGS method. Methods A total of 111 pulmonary nodule samples from 79 patients with multifocal lung adenocarcinoma were collected between January 2018 to May 2020 in the Molecular Diagnostic Center of Yunnan Cancer Hospital. The NGS method was used to detect the EGFR mutation of multiple lung nodules to analyze its relationship with clinicopathological characteristics, and Logistic regression to analyze its independent risk factors. Results The total EGFR mutation rate in 111 lung nodule tissue samples was 58.55% （65/111）, among which L858R point mutation and exon 19 deletion were the most common, accounting for 53.8%of the total mutations （35/65）.The rare mutation rate was 27.02% （30/111）, the single point mutation rate was 37.84% （42/111）, and the compound mutation rate was 20.72% （23/111）. χ² test showed that females, age ≥56 years, non-smoker, areas with a high incidence of lung cancer in Yunnan, earlier pathological stages （stages Ⅰ to Ⅱ）, and invasive adenocarcinoma had a higher EGFR gene mutation rate, and the difference was statistically significant （P = 0.036、P = 0.001、P < 0.001、P = 0.006、P = 0.006、P = 0.034）.Multivariate Logistic regression analysis showed thatage ≥56 years, non-smoker, areas with a high incidence of lung cancer in Yunnan, and earlier pathological stages （stages Ⅰ to Ⅱ） are independent risk factors for EGFR gene mutations （P＜0.05）.The heterogeneity rate of EGFR gene expression between paired nodules in the same patient was as high as 87.5% （28/32）. Conclusions Among patients with multinodular lung adenocarcinoma in Yunnan, the elderly, non-smoker, areas with a high incidence of lung cancer in Yunnan, and earlier pathological stages （stages Ⅰ to Ⅱ） are independent risk factors for EGFR gene mutations.The high-level heterogeneity of driver mutations among the lesions of patients with multinodular lung adenocarcinoma suggests that multiple nodules tend to be independent of the origin of the primary tumor, which will provide more options for the diagnosis and treatment of multinodular lung adenocarcinoma.
- Lung adenocarcinoma,
- Multiple pulmonary nodules,
- Epidermal growth factor receptor （EGFR）,
- Next-generation sequencing

FullText(HTML)

References(24)

References

[1]	Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424. doi: 10.3322/caac.21492
[2]	Zhang Y,Jheon S,Li H,et al. Results of low-dose computed tomography as a regular health examination among Chinese hospital employees[J]. J Thorac Cardiovasc Surg,2019,160(3):110-116.
[3]	Park E,Ahn S,Kim H,et al. Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepid ic Nodules[J]. J Thorac Oncol,2018,13(11):1776-1783. doi: 10.1016/j.jtho.2018.07.097
[4]	Chen K N. The diagnosis and treatment of lung cancer presented as ground-glass nodule[J]. Gen Thorac Cardiovasc Surg,2020,68(7):697-702. doi: 10.1007/s11748-019-01267-4
[5]	Detterbeck F C,Nicholson A G,Franklin W A,et al. The IASLC Lung Cancer Staging Project:Summary of Proposals for Revisions of the Classification of Lu ng Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification[J]. J Thorac Oncol,2016,11(5):639-650. doi: 10.1016/j.jtho.2016.01.024
[6]	John A,Yang B,Shah R. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Adv anced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data[J]. Adv Ther,2021,38(3):1552-1566. doi: 10.1007/s12325-020-01617-2
[7]	Liu Y,Zhang J,Li L,et al. Genomic heterogeneity of multiple synchronous lung cancer[J]. Nat Commun,2016,7:13200. doi: 10.1038/ncomms13200
[8]	Travis W D,Brambilla E,Nicholson A G,et al. The 2015 World Health Organization Classification of Lung Tumors:Impact of Genetic,Clinical and Rad iologic Advances Since the 2004 Classification[J]. J Thorac Oncol,2015,10(9):1243-1260. doi: 10.1097/JTO.0000000000000630
[9]	Hattori A,Matsunaga T,Takamochi K,et al. Surgical Management of Multifocal Ground-Glass Opacities of the Lung:Correlation of Clinicopathologi c and Radiologic Findings[J]. Thorac Cardiovasc Surg,2017,65(2):142-149.
[10]	中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2018年版)[J]. 中华结核和呼吸杂志,2018,10(41):110-116.
[11]	Naderi S,Ghorra C,Haddad F,et al. EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma:A si ngle institution experience[J]. Cancer Epidemiol,2015,39(6):1099-1102. doi: 10.1016/j.canep.2015.08.016
[12]	Passaro A,Prelaj A,Bonanno L,et al. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations[J]. Clin Lung Cancer,2019,20(2):186-194. doi: 10.1016/j.cllc.2018.11.005
[13]	Fan J,Dai X,Wang Z,et al. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multi focal Lesions[J]. Clin Lung Cancer,2019,20(4):517-530. doi: 10.1016/j.cllc.2019.04.008
[14]	Chen K,Chen W,Cai J,et al. Favorable prognosis and high discrepancy of genetic features in surgical patients with multiple prima ry lung cancers[J]. J Thorac Cardiovasc Surg,2018,155(1):371-391. doi: 10.1016/j.jtcvs.2017.08.141
[15]	Zhou Y,Yang Y,Yang C,et al. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China[J]. Oncotarget,2017,8(9):15023-15033. doi: 10.18632/oncotarget.14706
[16]	Hsu C H,Tseng C H,Chiang C J,et al. Characteristics of young lung cancer:Analysis of Taiwan's nationwide lung cancer registry focusing o n epidermal growth factor receptor mutation and smoking status[J]. Oncotarget,2016,7(29):46628-46635. doi: 10.18632/oncotarget.9338
[17]	王玉婕,冯昊,马山蕊,等. 同时性多原发肺腺癌表皮生长因子受体基因突变相关因素分析[J]. 中华医学杂志,2019,99(29):2297-301. doi: 10.3760/cma.j.issn.0376-2491.2019.29.010
[18]	Bao S M,Hu Q H,Yang W T,et al. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer:Current State and Future Pe rspective[J]. Anticancer Agents Med Chem,2019,19(8):984-991. doi: 10.2174/1871520619666190313161009
[19]	Liu M,He W X,Song N,et al. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multipl e ground-glass opacities[J]. Eur J Cardiothorac Surg,2016,50(5):909-913. doi: 10.1093/ejcts/ezw113
[20]	Chen G,Sun X,Ren H,et al. The mortality patterns of lung cancer between 1990 and 2013 in Xuanwei,China[J]. Lung Cancer,2015,90(2):155-160. doi: 10.1016/j.lungcan.2015.08.006
[21]	周永春,林艳苹,李权,等. 云南省肺癌患者表皮生长因子受体基因突变的临床特征分析[J]. 中华肿瘤杂志,2020,42(9):6.
[22]	Takahashi Y,Shien K,Tomida S,et al. Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis[J]. Cancer Sci,2018,109(11):3634-3642. doi: 10.1111/cas.13797
[23]	Saab J,Zia H,Mathew S,et al. Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis[J]. Transl Oncol,2017,10(3):442-449. doi: 10.1016/j.tranon.2017.02.009
[24]	Wu C,Zhao C,Yang Y,et al. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glas s Nodules[J]. J Thorac Oncol,2015,10(5):778-783. doi: 10.1097/JTO.0000000000000487

Relative Articles(20)

Relative Articles

[1]	Shengqiang YANG, Ping WANG. Effect of Hsp90 Inhibitor Ganetespib Combined with Pemetrexed on Lung Adenocarcinoma Cells. Journal of Kunming Medical University, 2024, 45(7): 30-41. doi: 10.12259/j.issn.2095-610X.S20240705
[2]	Wangxun SHEN, Yinyu YANG, Canwei LI, Jinrong YANG, Sijing WU, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1 in Different Histologic Types of Invasive Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20240509
[3]	Hongxiu YANG, Zhongshan ZHU. Effect of HPRT1 Gene Expression on Overall Survival of Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(8): 17-23. doi: 10.12259/j.issn.2095-610X.S20240803
[4]	Fei SONG, Jiayin CHE, Ming HUANG, Dan XU, Hongyang LI, Dingkun LI, Yingying XIANG. The Role of Radioactive Iodine-125 Particles in EMT and Clinical Treatment of Lung Adenocarcinoma. Journal of Kunming Medical University, 2023, 44(1): 140-143. doi: 10.12259/j.issn.2095-610X.S20230101
[5]	Shiqi MA, Yi DING, Min LI, Mengci WANG, Siyu ZHANG, Shumei FENG. LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway. Journal of Kunming Medical University, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
[6]	Bangqing LIU, Jianfeng LI, Xiaohui LIU, Jinnan ZHANG, Jinping LIANG. MiR-196b Promotes Proliferation and Migration of Lung Adenocarcinoma by Targeting ERG. Journal of Kunming Medical University, 2023, 44(10): 83-91. doi: 10.12259/j.issn.2095-610X.S20231023
[7]	Huajun ZHAO, Guoqing PAN, Ying TANG, Zhiyuan WANG, Xiaowei ZHAO, Xiaoyu TUO. Expressions of ROR1 in Lung Adenocarcinoma and Its Relationship with Spread Through Air Apace. Journal of Kunming Medical University, 2022, 43(11): 22-29. doi: 10.12259/j.issn.2095-610X.S20221128
[8]	Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912
[9]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2021, 42(8): 101-105. doi: 10.12259/j.issn.2095-610X.S20210818
[10]	Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549. Journal of Kunming Medical University, 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808
[11]	Yan-fen MA, Jian HU, Ning ZHANG, Qian WU, Xiao-qin WANG. Changes and Abnormal Patterns of Coagulation Indicators in Patients with Lung Adenocarcinoma and Tuberculosis Pleural Effusion. Journal of Kunming Medical University, 2021, 42(10): 145-150. doi: 10.12259/j.issn.2095-610X.S20211021
[12]	Ma Guo Yu , Xiong Qing , Jiang Guo Qing , Yang Jia Tian , Mu Yun Zhen . . Journal of Kunming Medical University, 2020, 41(07): 30-37.
[13]	Wu Qi Yan , Bian Ge Yuan , Cheng Hui Jun, Li Jiao Xia , Wang Shu Ting , Huang Zhao Lue . . Journal of Kunming Medical University, 2020, 41(09): 32-37.
[14]	Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University, 2018, 39(08): 47-50.
[15]	Qian Lu , Bian Li . Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms. Journal of Kunming Medical University, 2017, 38(08): 126-129.
[16]	Wang Hua . . Journal of Kunming Medical University,
[17]	. Expression of GDNF,BDNF,NT3 and NT4 in Human Lung Adenocarcinoma Cell Lines A549. Journal of Kunming Medical University,
[18]	. Expression of GDNF and Changes of Cell Viability of Lung Adenocarcinoma Cell Lines A549. Journal of Kunming Medical University,
[19]	. The Comparison of Cell Viability between Xuanwei Lung Adenocarcinoma Cell Lines xwlc-05 and Cell Lines A549 in Vitro. Journal of Kunming Medical University,
[20]	. Expression of study of Nestin in Lung Adenocarcinoma Cell Line A549. Journal of Kunming Medical University,